Markets:

Overview

News

Currencies

International

Treasuries

Teva Pharmaceutical Industries Limited American Depositary Shares (NY:TEVA)

28.11 -0.36 (-1.25%)

Streaming Delayed Price Updated: 11:05 AM EST, Dec 8, 2025 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Teva Pharmaceutical Industries Limited American Depositary Shares

< Previous 1 2 3 4 5 6 7 8 9

...

30 31 Next >

SciSparc Expands Biotech Ambitions, Buys Stake In Miza III Ventures ↗

October 15, 2025

SciSparc traded higher after the company announced it had signed a definitive agreement to acquire a controlling stake in Miza III Ventures.

Via Benzinga

Billionaire Stanley Druckenmiller Is Selling Nvidia and Palantir and Piling Into One of Wall Street's Hottest Drug Stocks Ahead of 2026 ↗

October 13, 2025

Druckenmiller is considered one of the best investors of all time.

Via The Motley Fool

Topics Artificial Intelligence Economy

FDA Approves Expanded Indication for UZEDY® (risperidone) Extended-Release Injectable Suspension as a Treatment for Adults Living with Bipolar I Disorder

October 10, 2025

From Teva Pharmaceutical Industries Ltd

Via GlobeNewswire

This Pharma Stock Is Down 19% In 2025 But Just Received An ‘Explosive News’ – Find Out More ↗

August 28, 2025

Via Stocktwits

Earnings Scheduled For July 30, 2025 ↗

July 30, 2025

Via Benzinga

Teva, Viatris On Investor Watch As White House Spares Generic Drugs From Tariffs ↗

October 09, 2025

The Trump administration backs off plans to impose tariffs on generic drugs after internal debate over price impacts and supply concerns.

Via Benzinga

Topics Government World Trade

SciSparc And AutoMax Call Off Merger ↗

October 06, 2025

SciSparc ends merger with AutoMax, sets loan repayment terms, and refocuses on CNS drug development and innovation.

Via Benzinga

Billionaire Stanley Druckenmiller Sold His Fund's Stakes in Nvidia and Palantir, and Has Piled Into These 2 Phenomenal Stocks for 4 Straight Quarters ↗

October 06, 2025

Duquesne Family Office's billionaire boss bid adieu to Wall Street's hottest AI stocks in favor of another trillion-dollar company and a long-awaited turnaround story in the healthcare sector.

Via The Motley Fool

Topics Artificial Intelligence Supply Chain

Teva Releases Q3 2025 Aide Memoire

September 25, 2025

From Teva Pharmaceutical Industries Ltd

Via GlobeNewswire

Teva to Host Conference Call to Discuss Third Quarter 2025 Financial Results at 8 a.m. ET on November 5, 2025

September 25, 2025

From Teva Pharmaceutical Industries Ltd

Via GlobeNewswire

Is Teva Pharmaceutical Indus Gaining or Losing Market Support? ↗

September 24, 2025

Via Benzinga

Trump Administration To Unveil Tylenol-Autism Review, Tout This Drug As Potential Treatment: Report ↗

September 22, 2025

Trump administration to announce concerns about Tylenol use in pregnancy and potential treatment for autism, in line with President's priority.

Via Benzinga

Topics Government

Patients Taking AUSTEDO XR® (deutetrabenazine) extended-release tablets Reported Symptom Improvement and High Satisfaction

September 20, 2025

From Teva Pharmaceutical Industries Ltd

Via GlobeNewswire

New Long-term Safety Data from the Completed Phase 3 SOLARIS Trial Support the Potential of Olanzapine LAI (TEV-'749) as the First Long-Acting Olanzapine Treatment Option for Schizophrenia with No PDSS Observed

September 20, 2025

From Teva Pharmaceutical Industries Ltd

Via GlobeNewswire

Teva to Host Conference Call to Discuss Data from the Completed Phase 3 SOLARIS Trial For Olanzapine LAI (TEV-‘749) on September 22, 2025 After Presentations at the Psych Congress Annual meeting

September 16, 2025

From Teva Pharmaceutical Industries Ltd

Via GlobeNewswire

Teva’s Emrusolmin Granted U.S. FDA Fast Track Designation for Treatment of Multiple System Atrophy

September 09, 2025

From Teva Pharmaceutical Industries Ltd

Via GlobeNewswire

Teva to Present at Morgan Stanley Global Healthcare Conference and Bank of America Global Healthcare Conference in September

September 02, 2025

From Teva Pharmaceutical Industries Ltd

Via GlobeNewswire

Should You Buy the 3 Highest-Paying Dividend Stocks in the Dow Jones? ↗

September 02, 2025

Are the Dow's biggest yields a bargain or a warning sign? Here's how the top payouts stack up, and what that could mean for income investors.

Via The Motley Fool

Topics Stocks

US-India Trade War Escalates: New Tariffs Spark Inflation Fears and Corporate Profit Warnings

August 29, 2025

The global trade landscape has once again been rattled as the United States officially implemented sweeping new tariffs on a significant portion of imports from India. Effective August 27, 2025, these...

Via MarketMinute

Topics Economy Government Supply Chain

Teva Launches Generic GLP-1 Weight Loss Drug With FDA Nod For Saxenda ↗

August 28, 2025

Teva launches the first U.S. generic version of Saxenda for weight loss after FDA approval, expanding its portfolio with a key GLP-1 therapy.

Via Benzinga

FDA Approves First-Ever Generic Weight-Loss Drug In A Blow To Novo Nordisk ↗

August 28, 2025

Teva Pharmaceutical is joining compounders, knocking off one of Novo Nordisk's weight-loss drugs.

Via Investor's Business Daily

Teva Announces FDA Approval and Launch of Generic Saxenda® (liraglutide injection) – First Generic GLP-1 Indicated for Weight Loss

August 28, 2025

From Teva Pharmaceutical Industries Ltd

Via GlobeNewswire

10 Health Care Stocks With Whale Alerts In Today's Session ↗

August 21, 2025

Via Benzinga

Billionaire Stanley Druckenmiller Sold All of His Palantir and Has Piled Into This High-Flying Drug Stock for 4 Consecutive Quarters ↗

August 20, 2025

Duquesne's billionaire boss bid adieu to Wall Street's hottest artificial intelligence (AI) stock in favor of one of the cheapest pharmaceutical stocks on the planet.

Via The Motley Fool

Topics Artificial Intelligence

How Is The Market Feeling About Teva Pharmaceutical Indus? ↗

August 18, 2025

Via Benzinga

FDA Approves Expanded Indication for AJOVY® (fremanezumab-vfrm), The First Anti-CGRP Preventive Treatment for Pediatric Episodic Migraine

August 06, 2025

From Teva Pharmaceutical Industries Ltd

Via GlobeNewswire

Teva Pharma Boosts Outlook For Key Innovative Drugs Austedo, Ajovy, Uzedy ↗

July 30, 2025

Teva raised 2025 guidance for Austedo, Ajovy, and Uzedy after Q2 earnings beat estimates, despite missing revenue expectations.

Via Benzinga

Topics Earnings

Why Drugmaker Teva Pharmaceutical Narrowed Full-Year Guidance After Beating Q2 Earnings ↗

July 30, 2025

Teva stock is trading below key levels.

Via Investor's Business Daily

Teva's Innovative Portfolio Fuels 10th Consecutive Quarter of Growth in Q2 2025; Increases 2025 Revenue Outlook for Key Innovative Products and EPS, and Reaffirms All Other Components

July 30, 2025

From Teva Pharmaceutical Industries Ltd

Via GlobeNewswire

Generic Revlimid Fades, But Teva's Broader Generics Outlook Remains Strong ↗

July 29, 2025

Teva anticipates EBITDA recovery post-2025 as Austedo and Uzedy grow and generic Revlimid faces rising competition.

Via Benzinga

< Previous 1 2 3 4 5 6 7 8 9

...

30 31 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.